As Merck & Co. INC (MRK) Stock Value Rose, Chesley Taft & Associates LLC Has Lifted Holding by $5.96 Million

September 14, 2018 - By Palma Niemeyer

Merck & Co., Inc. (NYSE:MRK) LogoInvestors sentiment is 1 in 2018 Q2. Its the same as in 2018Q1. It is the same, as 48 investors sold MRK shares while 608 reduced holdings. only 126 funds opened positions while 530 raised stakes. 1.88 billion shares or 1.46% less from 1.91 billion shares in 2018Q1 were reported. Jane Street Gp Ltd Company has 0.02% invested in Merck & Co., Inc. (NYSE:MRK). Schulhoff Co reported 10,665 shares. Apriem Advsrs has 10,766 shares for 0.15% of their portfolio. Jolley Asset Limited Liability reported 58,460 shares. Forbes J M & Ltd Liability Partnership owns 156,866 shares for 2.13% of their portfolio. 5,800 were accumulated by Montag & Caldwell Limited Liability Co. Uss Inv holds 774,350 shares or 0.51% of its portfolio. Cadence Cap Ltd Liability Co has invested 0.65% in Merck & Co., Inc. (NYSE:MRK). Wagner Bowman Mngmt accumulated 22,845 shares or 0.36% of the stock. Patten & Patten Tn invested in 140,814 shares. Hm Cap Limited Liability Corporation accumulated 0.17% or 3,633 shares. Acg Wealth accumulated 44,820 shares. Fragasso Gp Incorporated has 6,353 shares. Canandaigua Retail Bank And Co reported 1.05% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Bnp Paribas Arbitrage owns 3.22 million shares.

Chesley Taft & Associates Llc increased its stake in Merck & Co. Inc. (MRK) by 125.51% based on its latest 2018Q2 regulatory filing with the SEC. Chesley Taft & Associates Llc bought 99,409 shares as the company’s stock rose 11.62% with the market. The institutional investor held 178,612 shares of the health care company at the end of 2018Q2, valued at $10.84M, up from 79,203 at the end of the previous reported quarter. Chesley Taft & Associates Llc who had been investing in Merck & Co. Inc. for a number of months, seems to be bullish on the $185.90 billion market cap company. The stock decreased 0.64% or $0.45 during the last trading session, reaching $69.9. About 2.59 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 6.72% since September 14, 2017 and is uptrending. It has underperformed by 8.90% the S&P500.

More recent Merck & Co., Inc. (NYSE:MRK) news were published by: 247Wallst.com which released: “Short Sellers Back Off Major Pharma Stocks” on September 13, 2018. Also Investorplace.com published the news titled: “Friday’s Vital Data: Apple, Advanced Micro Devices and Merck” on September 14, 2018. 247Wallst.com‘s news article titled: “Apple, IBM Lift the Dow Thursday” with publication date: September 13, 2018 was also an interesting one.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 8 analysts covering Merck & Company (NYSE:MRK), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Merck & Company had 12 analyst reports since March 23, 2018 according to SRatingsIntel. As per Tuesday, April 17, the company rating was upgraded by Morgan Stanley. The stock of Merck & Co., Inc. (NYSE:MRK) has “Hold” rating given on Friday, April 20 by Cowen & Co. As per Friday, March 23, the company rating was maintained by Jefferies. The rating was maintained by Guggenheim with “Buy” on Tuesday, April 17. The firm has “Buy” rating by Goldman Sachs given on Monday, April 23. The firm earned “Outperform” rating on Thursday, April 26 by BMO Capital Markets. Bank of America maintained Merck & Co., Inc. (NYSE:MRK) rating on Tuesday, April 17. Bank of America has “Buy” rating and $70 target. The firm has “Overweight” rating given on Thursday, August 23 by Morgan Stanley. Barclays Capital upgraded the stock to “Overweight” rating in Thursday, April 5 report. Jefferies maintained it with “Hold” rating and $5600 target in Friday, April 13 report.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.